IDT Biologika receives 2015 FOYA award from the International Society for Pharmaceutical Engineering

Vaccine producer is the recipient of the 2015 Facility of the Year Award for facility integration

Sponsored by the International Society for Pharmaceutical Engineering, the award spotlights companies that set the standard in pharmaceutical facility design, integration and operational excellence.

Completing a major expansion of its biologics and vaccines production facility in Germany last year, IDT Biologika established highly automated filling and freeze-drying operations, providing the basis for large-scale commercial manufacturing and high quality aseptic operations.

‘With this new facility, the company can now produce an evermore diverse range of biotechnologies with extraordinary precision, safety and integrity,' said Dr Ralf Pfirmann, IDT’s Chief Executive Officer.

‘Designed to be modular, fast and expandable, the IDT Biologika facility is now one of the most flexible biologics operations in the world,’ said Dr Andreas Neubert, head of IDT’s vaccines business unit. ‘Creating a future-proof and flexible production structure has given IDT the leeway it needed to move a number of projects from the incubator to fill-and-finish, freeze-dry, storage or the market with state-of-the-art quality, better economics and operational efficiency.’

‘Everyone at IDT Biologika believes this facility is proof that excellence in facility design and integration is a winning formula for the biopharmaceutical supply chain, including the millions of patients around the globe that need access to new and affordable vaccines. Speaking on behalf of the scientists, technicians and facility construction experts at IDT Biologika who made this multipurpose facility a reality, I thank the 2015 FOYA judging panel for recognising this project as being vital to the future of affordable biologic medicines,’ said Dr Pfirmann.

A major manufacturer of human vaccines designed to address some of the world’s most challenging infectious diseases, IDT Biologika expanded its vaccine production from two to three buildings, extending its large-scale commercial production capacities. With a major expansion and integration complete, the company is now equipped to manufacture up to 100 million vials per year.

IDT Biologika now offers one of the most dynamic, integrated facilities designed for biomedical product development and manufacturing at one location. The company is unique in its ability to accommodate the development, testing and manufacture of vital vaccines and other biological products for the world’s leading biopharmaceutical companies.

Companies